Expanding hepatitis C treatment would “more than offset direct spending on that treatment,” according to a report from the Congressional Budget Office released Friday (June 14), but advocates say the report is still incomplete. CBO also called for more research on outreach to patients, hepatitis C treatment with direct-acting antiviral medications (DAAs), and the costs of not treating hepatitis C. Sources previously told Inside Health Policy that Senate health committee ranking Republican Sen. Bill Cassidy (LA) and Sen. Chris...